Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®
22 Februar 2022 - 3:00PM
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
company focused on the treatment of primary and metastatic cancers
of the liver, announced today that effective March 1, 2022, it will
resume direct responsibility for sales, marketing and distribution
activities relating to the CHEMOSAT® Hepatic Delivery System in
Europe (EU, United Kingdom, Norway, Liechtenstein, Switzerland).
Since December 2018, medac GmbH, a privately held, multi-national
pharmaceutical company based in Germany, has been the licensee for
CHEMOSAT in Europe. Delcath and medac are working closely together
on an orderly transition of activities.
CHEMOSAT is the European trade name for Delcath’s proprietary
percutaneous hepatic perfusion (PHP) device, which administers a
high-dose chemotherapeutic agent (melphalan hydrochloride) to the
liver, while controlling systemic exposure. Delcath launched
CHEMOSAT in the EU in 2012 and sold the product through its own
dedicated sales force up until the 2018 licensing agreement.
“Delcath is eager to resume direct sales and distribution in
Europe and will work closely with medac during the transfer process
to ensure patients continue to receive access to CHEMOSAT
treatment,” said Gerard Michel, CEO of Delcath.
About Delcath
Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company’s proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the PHP system is being developed
under the tradename HEPZATO™ KIT (melphalan hydrochloride for
injection/hepatic delivery system), or HEPZATO, and is considered a
combination drug and device product regulated by the United States
Food and Drug Administration (FDA).
In Europe, the PHP system is regulated as a Class IIb medical
device and is approved for sale under the trade name CHEMOSAT
Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has
been used at major medical centers to treat a wide range of cancers
of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James Carbonara
(646)-755-7412james@haydenir.com
Source: Delcath Systems, Inc.
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024